Martomo SA, Yang WW, Vaisman A, Maas A, Yokoi M, Hoeijmakers JH, Hanaoka F, Woodgate R, Gearhart PJ. Normal hypermutation in antibody genes from congenic mice defective for DNA polymerase iota. DNA Repair. 2006; 5:392-8. McIlwraith MJ, Vaisman A, Liu Y, Fanning
E, Woodgate R, and West SC. Human DNA Polymerase eta Promotes DNA
Synthesis from Strand Invasion Intermediates (D-loops) of Homologous Recombination. Mol Cell. 2005; 20:783-92. Vaisman A, Takasawa K, Iwai S, and Woodgate R. DNA polymerase
iota-dependent translesion replication of uracil containing cyclobutane
pyrimidine dimers. DNA Repair. 2005; 5:210-8. Vaisman A, Ling H, Woodgate R, and Yang W. (2005) Fidelity
of Dpo4: effect of metal ions, nucleotide selection and pyrophosphorolysis. EMBO J. 24: 2957-67. Wilson TM, Vaisman A, Martomo SA, Sullivan P, Lan L, Hanaoka F, Yasui A,
Woodgate R, and Gearhart PJ. (2005) MSH2-MSH6
stimulates DNA polymerase eta, suggesting a role for A:T mutations in immunoglobulin
genes. J. Exp. Med. 201:637-45. Vaisman A and Woodgate R. (2004) DNA Eukaryotic Translesion DNA Polymerases. Encyclopedia
of Biol. Chem. 4:247-50. Vaisman A, Lehmann AR, Woodgate R. (2004) DNA Polymerases
eta and iota. Adv Protein Chem. 69:205-28. Ghadessy FJ, Ramsay N, Boudsocq F, Loakes D, Brown A, Iwai S, Vaisman A,
Woodgate R, Holliger P. (2004) Generic
expansion of the substrate spectrum of a DNA polymerase by directed evolution. Nat
Biotechnol. 22:755-9 Boudsocq F, Kokoska RJ, Plosky BS, Vaisman A, Ling H, Kunkel TA, Yang W,
Woodgate R. (2004) Investigating the role of the little finger domain of Y-family DNA polymerases
in low fidelity synthesis and translesion replication. J Biol Chem. 279:32932-40. Bassett E, Vaisman A, Havener JM, Masutani C, Hanaoka F, Chaney SG. (2003) Efficiency
of extension of mismatched primer termini across from cisplatin and oxaliplatin
adducts by human DNA polymerases beta and eta in vitro. Biochemistry,42:14197-206. Vaisman A, Frank EG, Iwai S, Ohashi E, Ohmori H, Hanaoka F, Woodgate R.
(2003) Sequence
context-dependent replication of DNA templates containing UV-induced lesions
by human DNA polymerase iota. DNA Repair 2:991-1006. Bassett E, Vaisman A, Tropea KA, McCall CM, Masutani C, Hanaoka F, Chaney
SG. (2002) Frameshifts
and deletions during in vitro translesion synthesis past Pt-DNA adducts
by DNA polymerases beta and eta. DNA Repair 1:1003-16. Vaisman A, Frank EG, McDonald JP, Tissier A, Woodgate R. (2002) poliota-dependent
lesion bypass in vitro. Mutat Res. 510: :9-22. Vaisman A, Woodgate R. (2001) Unique
misinsertion specificity of poliota may decrease the mutagenic potential
of deaminated cytosines. EMBO J. 20: 6520-9. Vaisman A, Tissier A, Frank EG, Goodman MF, Woodgate R. (2001) Human
DNA polymerase iota promiscuous mismatch extension. J Biol Chem. 276:30615-22. Tissier A, Frank EG, McDonald JP, Vaisman A, Fernandez de Henestrosa AR,
Boudsocq F, McLenigan MP, Woodgate R. (2001) Biochemical
characterization of human DNA polymerase iota provides clues to its biological
function. Biochem Soc Trans., 29:183-7. Vaisman A, Warren MW, Chaney SG. (2001) The
effect of DNA structure on the catalytic efficiency and fidelity of human
DNA polymerase b on templates with platinum-DNA
adducts. J Biol Chem, 276:18999-9005. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV,
Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. (2000) Oxaliplatin-induced
damage of cellular DNA. Mol Pharmacol. 58: 920-7. Vaisman A, Chaney SG. (2000) The
efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin
GpG adducts by human DNA polymerase beta. J Biol Chem. 275:
13017-25. Vaisman A, Masutani C, Hanaoka F, Chaney SG. (2000) Efficient
translesion replication past oxaliplatin and cisplatin GpG adducts by human
DNA polymerase eta. Biochemistry, 39: 4575-80. Chaney S.G.and Vaisman A. (1999) Specificity
of Platinum DNA Adduct Repair. Journal of Inorganic Biochemistry, 77:71-81. Chaney S.G.,Vaisman A., DNA adduct tolerance and bypass. Platinum-Based
Drugs in Cancer Therapy, Chapter 6, Humana Press, Totowa, NJ, 129-148. Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle
DC, Turchi JJ, Chaney SG: (1999). The
Effect of DNA Polymerases and HMG1 on the Carrier Ligand Specificity for
Translesion Synthesis Past Pt-DNA Adducts, Biochemistry, 38:11026-11039. Reardon JT, Vaisman A, Chaney SG, and Sancar A (1999). Efficient
Nucleotide Excision Repair of Cisplatin, Oxaliplatin and JM216 Platinum
Intrastrand DNA Diadducts Cancer Res., 59:3968-3971. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T.A., Risinger, J.I., Barrett,
J.C., Hamilton, T.C., & Chaney, S.G. (1998). The
role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance:
correlation with replicative bypass of platinum- DNA adducts. Cancer
Res., 58, 3579-3585. Vaisman, A., Varchenko, M., Said, I., & Chaney, S.G. (1997). Cell
cycle changes associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry, 27,
54-64. Delmastro, D.A., Li, J., Vaisman, A., Solle, M., & Chaney, S.G. (1997). DNA
damage inducible-gene expression following platinum treatment in human
ovarian carcinoma cell lines. Cancer Chemother.Pharmacol., 39,
245-253. Vaisman, A., Keeney, S., Nichols, A.F., Linn, S., & Chaney, S.G. (1996). Cisplatin-induced
alterations in the expression of the mRNAs for UV- damage recognition protein. Oncol.Res., 8,
7-12. Shea T., Graham M., Bernard S., Steagall A., Wiley
J., Serody J., Brecher M., Bentley S. Johnston C.,
Vaisman A., Chaney S.G., Letrent S., Brouer K. A
clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel,
granulocyte colony-stimulating factor, and peripheral blood stem cells
in patients with unresectable or metastatic cancer. Seminars
in Oncology. 1995, 22, 80-5. Vaisman, A. & Chaney, S.G. (1995). Induction
of UV-damage recognition protein by cisplatin treatment. Biochemistry, 34,
105-114. Thompson, D.C., Vaisman, A., Sakata, M.K., Wyrick, S.D., Holbrook, D.J., & Chaney, S.G. (1995). Organ-specific biotransformation of ormaplatin in the Fischer 344 rat. Cancer Chemother.Pharmacol., 36, 439-447.
|